Predictive Oncology Inc. (NASDAQ: POAI) Taps Its Chairman to be CEO

• Current POAI Chairman J. Melville (“Mel”) Engle has been appointed to CEO position
• Engle has held executive positions throughout his career at leading pharma and medical device companies, including Dey L.P. (a subsidiary of Merck KGaA), Allergan, Anika Therapeutics and Thermogenesis
• During his time at Merck’s Dey L.P., Engle transitioned the company from generics to branded products and grew sales from $250 million to $600 million

The world today uses big data for all sorts of predictions, especially consumer behavior. One day, though, big data and technology could prove even more valuable as the catalyst to flip the healthcare script from one that is almost exclusively reactive, to a proactive one that foretells disease at best and eliminates trial and error in therapy decisions after a disease presents at worst. That’s the hope of Predictive Oncology (NASDAQ: POAI), a company using an extensive dataset collected over the last 15 years to better inform individualized cancer therapies today as it advances development of its predictive tumor profiling technology rooted in its artificial intelligence (“AI”) platform.

The company recently named J. Melville (“Mel”) Engle as chief executive officer. Engle has been a director at POAI since October 2016 and has sat as chairman of the board since January 2020. He will take on the top executive role and continue to…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.